Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12068406 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Azepane SCHEMBL11361504 | 1.00 | — | — | |
| SCHEMBL3498160 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL8435190 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL11508384 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL3069642 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL11283826 | 1.00 | — | — | |
| SCHEMBL21753221 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL21819962 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL6890150 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2013-07-25 | — | — | US | disclosed |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-08-23 | — | — | US | disclosed |
| WO-2006133242-A2 | AZINONE AND DIAZINONE V3 INHIBITORS FOR DEPRESSION AND STRESS DISORDERS | PHARMACOPEIA, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | HAVCR2, RNASE1, RNASEH1 | ALDH1A1 548/4885CXCR4 502/4885SMN1; SMN2 662/4885 |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | BCL2, BAX, BAD | ALDH1A1 4519/4885CXCR4 1049/4885SMN1; SMN2 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.